BA
CRL icon

Boston Advisors’s Charles River Laboratories CRL Stock Holding History

Boston Advisors’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-6,465
Closed -$708K – 641
2017
Q4 		$708K Buy
+6,465
New +$704K 0.02% 434
2017
Q2 		– Sell
-9,580
Closed -$862K – 649
2017
Q1 		$862K Sell
9,580
-12,035
-56% -$1.02M 0.02% 379
2016
Q4 		$1.65M Buy
21,615
+1,650
+8% +$125K 0.04% 309
2016
Q3 		$1.66M Buy
19,965
+15,895
+391% +$1.33M 0.04% 298
2016
Q2 		$336K Buy
+4,070
New +$335K 0.01% 574

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Boston Advisors's CRL Position: Q1 2018 in Review

Boston Advisors sold out of Charles River Laboratories (CRL) in Q1 2018, closing a stake of 6,465 shares — an estimated $708K sold.

Boston Advisors first reported a position in CRL in Q2 2016 and held it in 5 quarters. The position peaked at $1.66M in Q3 2016. 333 funds tracked by Wall St. Rank hold CRL as of Q1 2018.

  • Boston Advisors reported no remaining Charles River Laboratories position as of Q1 2018 after selling out during the quarter.
  • Boston Advisors sold 6,465 Charles River Laboratories shares in Q1 2018, an estimated $708K.
  • Boston Advisors first reported a position in Charles River Laboratories in Q2 2016 and held it in 5 quarters.
  • Boston Advisors's Charles River Laboratories position peaked at $1.66M in Q3 2016.
  • 333 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2018.

Based on Boston Advisors's 13F filing for Q1 2018, filed 25 Apr 2018.